Carmell Co. (NASDAQ:CTCX) Short Interest Update

Carmell Co. (NASDAQ:CTCX) was the recipient of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 94,200 shares, a decrease of 66.8% from the January 31st total of 284,100 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily volume of 6,440,000 shares, the short-interest ratio is presently 0.0 days.

Carmell Stock Performance

NASDAQ CTCX remained flat at $0.24 during trading on Friday. 177,589 shares of the company’s stock were exchanged, compared to its average volume of 8,761,643. Carmell has a one year low of $0.20 and a one year high of $3.35. The business’s fifty day moving average is $0.37 and its two-hundred day moving average is $0.41.

Hedge Funds Weigh In On Carmell

An institutional investor recently bought a new position in Carmell stock. Citadel Advisors LLC purchased a new position in shares of Carmell Co. (NASDAQ:CTCX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 187,565 shares of the company’s stock, valued at approximately $54,000. Citadel Advisors LLC owned about 0.90% of Carmell at the end of the most recent reporting period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Carmell Company Profile

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.